Tabula Rasa (TRHC) is a healthcare service provider with ~25% sustainable growth in recurring revenue, expanding gross margins and a model that is very likely to generate 20% EBITDA margins over the long term.

As you can see from the company snapshot growth is healthy. With 16.1M shares outstanding post-IPO the market capitalization is $241M at $15/share which is the upper end of the proposed price range.

The core of what TRHC does is prevent nasty drug interactions in patients. There's a lot to take into account, especially since many patients, especially older ones, can be . . .

Want the rest of the article?

Please login or join us as a member to view our complete content!